Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioDynamics ( (GB:OBD) ) has provided an update.
Oxford BioDynamics has announced interim results from its PROWES trial, showcasing the clinical utility of its EpiSwitch CiRT test in guiding treatment decisions for patients undergoing immune checkpoint inhibitor therapy. The study, published in the journal Cancers, demonstrated that the CiRT test influenced treatment choices in 61% of cases, helping oncologists make more informed decisions. The test’s ability to predict patient responses with high sensitivity and specificity could lead to significant cost savings by avoiding ineffective treatments. The company plans to apply for inclusion in the US National Comprehensive Cancer Network clinical guidelines, aiming for broader adoption and commercial success.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, characterized by continuous net losses and negative cash flows. Technical analysis provides some neutral signals, but the valuation remains unattractive due to a negative P/E ratio and no dividend yield. The lack of earnings call data and corporate events further limits the potential for a higher score.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company that specializes in developing and commercializing precision clinical diagnostic tests for life-changing diseases. The company offers products like the EpiSwitch® PSE and EpiSwitch® CiRT blood tests, which are based on its proprietary 3D genomic biomarker platform, EpiSwitch®. These tests are designed to enhance predictive accuracy for diseases like prostate cancer and to guide immuno-oncology treatments. The company operates in the UK, USA, and Malaysia and is listed on the London Stock Exchange’s AIM.
Average Trading Volume: 40,580,384
Technical Sentiment Signal: Sell
Current Market Cap: £8.81M
See more insights into OBD stock on TipRanks’ Stock Analysis page.